tbuckley/cabot-search huggingface dataset:
A case of unresectable Stage IV HER2-positive advanced gastric cancer treated by using trastuzumab combined with SOX
Authors: Tatsuo Horie, Kazuo Mizumoto, Sigeru Sakano, Miyako Horie, Hirokazu Ishibashi, Masahiko Takahashi, Satoshi Honda, Yoshihiro Noso
Journal: Annals of Oncology (2015)
Association of a Genetic Risk Score With Body Mass Index
Authors: Marcus R. Munafò, Kate Tilling, George Davey Smith
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
CD61/ Integrin β3 Ligation Contributes to the Thrombopoietin-Mediated Niche Function of Mouse Hematopoietic Stem Cells.
Authors: Terumasa Umemoto, Masayuki Yamato, Yoshiko Shiratsuchi, Kenji Tsukada, Mika Utsumi, Yohei Morita, Masato Terasawa, Takehiko Shibata, Kohji Nishida, Yoshiro Kobayashi, Brian G Petrich, Mark H Ginsberg, Hiromitsu Nakauchi, Koji Eto, Teruo Okano
Journal: Blood (2009)
182P Phase II clinical trial of adjuvant chemotherapy with mFOLFOX6/XELOX for stage III colon cancer in Japanese subjects
Authors: T. Yamada, K. Koda, K. Ishibashi, H. Kato, G. Nishimura, S. Ooki, K. Yoshimatsu, E. Uchida, H. Kan, C. Kosugi, S. Tanaka, R. Kato, S. Kouketsu, H. Nakajima, H. Maekawa, M. Kobayashi, M. Tsubaki, M. Yokoyama, K. Tanakaya, H. Ishida
Journal: Annals of Oncology (2015)
Unusual Abdominal Tumors
Authors: C.S. Chim, T.W.H. Shek, L.P. Chung, R. Liang
Journal: Journal of Clinical Oncology (2003)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2003.02.032 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 12610202 Unusual Abdominal Tumors CASE 3. MULTIPLE LYMPHOMATOUS POLYPOSIS IN LYMPHOMA OF COLON C.S. ChimxC.S. ChimSearch for articles by this author , T.W.H. ShekxT.W.H. ShekSearch for articles by this author , L.P. ChungxL.P. ChungSearch for articles by this author , R. LiangxR. LiangSearch for articles by this author Show More University Departments of Medicine and Pathology, Queen Mary Hospital, University of Hong Kong, Hong Kong, People’s Republic of China https://doi.org/10.1200/JCO.2003.02.032 First Page Full Text PDF Figures and Tables © 2003 by American Society of Clinical Oncology
Liver Specific Delivery of siRNA Targeting EGLN Prolyl Hydroxylases Activates Hepatic Erythropoietin Production and Stimulates Erythropoiesis,
Authors: William Querbes, Roman Bogorad, Javid Moslehi, Akin Akinc, Jamie Wong, Chris Zurenko, June Qin, Julia Hettinger, Satya Kuchimanchi, Klaus Charisse, Dinah WY Sah, Kevin Fitzgerald, Victor Kotelianski, William G. Kaelin
Journal: Blood (2011)
Chemopreventive Effects of ROS Targeting in a Murine Model of BRCA1-Deficient Breast Cancer
Authors: Mo Li, Qian Chen, Xiaochun Yu
Journal: Cancer Research (2016)

There remains great interest in practical strategies to limit the elevated risks of familial breast and ovarian cancers driven by BRCA1 mutation. Here, we report that limiting the production of reactive oxygen species (ROS) is sufficient to reduce DNA lesions and delay tumorigenesis in a murine model of BRCA1-deficient breast cancer. We documented a large amount of endogenous estrogen oxidative metabolites in the mammary gland of the model, which induced DNA adducts and apurinic/apyrimidinic sites associated with DNA double-strand breaks and genomic instability. Repressing estrogen oxidation via antioxidant treatments reduced oxidative DNA lesions and delayed the onset of mammary tumors. Overall our work suggests an answer to the long-standing question of why germline BRCA1 mutations cause tissue-specific tumors, in showing how tissue-specific, ROS-induced DNA lesions create a nongenetic force to promote mammary tumors in BRCA1-deficient mice. Our findings create a rationale for evaluating suitable antioxidant modalities as a chemopreventive strategy for familial breast cancer. Cancer Res; 77(2); 448-58. ©2016 AACR.
Autoimmune Lymphoproliferative Syndrome (ALPS) and ALPS-Related Disorders. Different Bio-Clinical Profile and Similar Response to Treatment: A Single Centre Experience
Authors: Maurizio Miano, Andrea Todiere, Ilaria Caviglia, Elena Palmisani, Johanna Svahn, Concetta Micalizzi, Paola Terranova, Tiziana Lanza, Carlo Dufour, Francesca Fioredda
Journal: Blood (2015)
P0770 : Effect of hepatitis C antiviral therapy on all-cause mortality and development of cancer in the chronic hepatitis cohort study (CHeCS)
Authors: M. Lu, J. Li, L.B. Rupp, S.D. Holmberg, A.C. Moorman, P.R. Spradling, E. Teshale, F. Xu, J.A. Boscarino, V. Vijayadeva, M.A. Schmidt, L.E. Lamerato, S. Gordon
Journal: Journal of Hepatology (2015)
Eculizumab Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). the Argentinian Experience
Authors: Andres L. Brodsky, Valeria Soledad Touliet, Adriana Rocaspana, Ximena Aldunate, Abel Esteban Alzueta, Teresa Barraza, Raul Beguelin, Gabriel Campregher, Laura Beatriz Colin, Pablo Dinardo, Daniel Gotta, Natalia Oliveira, Claudia Parodi, Gabriela Perinotto, Mario Ramirez, Guillermina Rigada, Rosanna Ronzzetti, Rosenfeld Esther, Rossi Blanca, Miriam Stivel, Sandra Zirone
Journal: Blood (2015)
EFFECT OF CARBOHYDRATE-ELECTROLYTE-PROTEIN SOLUTION INGESTION ON 21 KM RUNNING PERFORMANCE IN FEMALE MARATHON RUNNERS
Authors: F SUN, Z GUI
Journal: British Journal of Sports Medicine (2016)

The purpose of the present study was to compare the effects of carbohydrate-electrolyte-protein solutions (CEPS), carbohydrate-electrolyte solutions (CES), and placebo (PLA) consumption on 21 km running performance in female runners. Nine healthy recreational female marathon runners (Age 36±7 y, BMI 21.0±2.3 kg/m 2 , V O 2max 48.4±6.8 ml/kg/min) completed 3 experimental trials in a randomized crossover study design, separated by at least 30 days. All the main trials were required to be finished in their follicular phase. In each main trial, participants were required to complete one 21 km performance running. For the first 5 km, the participants ran at a fixed speed of their individual 70% V O 2max. Thereafter, the participants ran at whatever speed they wished for the remaining 16 km of the performance run. Every 2.5 km throughout the run, 150 ml of solutions was provided to the participants. The three solutions were CES (6%CHO), CEPS (4%CHO+2%PRO), and a non-caloric, artificially sweetened PLA. Three solutions contained the same electrolyte profile. Total energy was matched between CES and CEPS. No differences was found in remaining 16 km running performance among the three trials, with mean times of 103.3±3.1, 98.7±1.9, and 103.1±2.9 min for CEPS, CES and PLA trials, respectively. Blood glucose concentration was lower in PLA trial (4.5±0.1 mmol/L) than CES trial (5.6±0.2 mmol/L) ( P =0.004). Blood lactate was higher in CES trial (2.5±0.3 mmol/L) than CEPS trial (1.8±0.2 mmol/L) ( P =0.043). It seems that neither CES nor CEPS consumption during a 21 km run can improve exercise performance in recreational female marathon runners. The present study was supported by Dean's Research Fund (FLASS/DRF/ECR-2), Faculty of Liberal Arts and Social Sciences, The Education University of Hong Kong.
Geographic and Racial/Ethnic Differences in HFE Mutation Frequencies and Iron Phenotypes in the Hemochromatosis and Iron Overload Screening (HEIRS) Study.
Authors: Ronald T. Acton, Beverly M. Snively, James C. Barton, Paul C. Adams, John H. Eckfeldt, Emily L. Harris, Fitzroy W. Dawkins, Christine E. McLaren, Victor R. Gordeuk, Gordon D. McLaren, David M. Reboussin, Phyliss Sholinsky, Mark R. Speechley, Joan Holup, Cathy Leiendecker-Foster
Journal: Blood (2004)
Concomitantly Targeting BCL-2 with Venetoclax (ABT-199/GDC-0199) and MAPK Signaling with Cobimetinib (GDC-0973) in Acute Myeloid Leukemia Models
Authors: Lina Han, Qi Zhang, Ce Shi, Joel Leverson, Monique Dail, Darren C. Phillips, Jun Chen, Sha S Jin, Rodrigo Omar Jacamo, Naval Daver, Elias J Jabbour, Hagop M Kantarjian, Michael Andreeff, Deepak Sampath, Marina Konopleva
Journal: Blood (2015)
Serum Metabolomic Profiles in Neonatal Mice following Oral Brominated Flame Retardant Exposures to Hexabromocyclododecane (HBCD) Alpha, Gamma, and Commercial Mixture
Authors: David T. Szabo, Wimal Pathmasiri, Susan Sumner, Linda S. Birnbaum
Journal: Environmental Health Perspectives (2016)

Hexabromocyclododecane (HBCD) is a high production volume brominated flame retardant added to building insulation foams, electronics, and textiles. HBCD is a commercial mixture (CM-HBCD) composed of three main stereoisomers: α-HBCD (10%), β-HBCD (10%), and γ-HBCD (80%). A shift from the dominant stereoisomer γ-HBCD to α-HBCD is detected in humans and wildlife.Considering CM-HBCD has been implicated in neurodevelopment and endocrine disruption, with expected metabolism perturbations, we performed metabolomics on mice serum obtained during a window-of-developmental neurotoxicity to draw correlations between early-life exposures and developmental outcomes and to predict health risks.Six female C57BL/6 mice at postnatal day (PND) 10 were administered a single gavage dose of α-, γ-, or CM-HBCD at 3, 10, and 30 mg/kg. Nuclear magnetic resonance metabolomics was used to analyze 60 μL serum aliquots of blood collected 4 days post-oral exposure.Infantile mice exposed to α-, γ-, or CM-HBCD demonstrated differences in endogenous metabolites by treatment and dose groups, including metabolites involved in glycolysis, gluconeogenesis, lipid metabolism, citric acid cycle, and neurodevelopment. Ketone bodies, 3-hydroxybutyrate, and acetoacetate, were nonstatistically elevated, when compared with mean control levels, in all treatment and dose groups, while glucose, pyruvate, and alanine varied. Acetoacetate was significantly increased in the 10 mg/kg α-HBCD and was nonsignificantly decreased with CM-HBCD. A third ketone body, acetone, was significantly lower in the 30 mg/kg α-HBCD group with significant increases in pyruvate at the same treatment and dose group. Metabolites significant in differentiating treatment and dose groups were also identified, including decreases in amino acids glutamate (excitatory neurotransmitter in learning and memory) and phenylalanine (neurotransmitter precursor) after α-HBCD and γ-HBCD exposure, respectively.We demonstrated that 4 days following a single neonatal oral exposure to α-, γ-, and CM-HBCD resulted in different serum metabolomic profiles, indicating stereoisomer- and mixture-specific effects and possible mechanisms of action.
P0737 : Meld score kinetics and survival in HIV/HCV patients: The ANRS EP 25 prethevic cohort
Authors: M. Gelu-Simeon, T. Bayan, M. Ostos, F. Boufassa, J.-M. Steyaert, I. Bertucci, E. Teicher, R. Anty, G.-P. Pageaux, L. Meyer, J.-C. Duclos-Vallee
Journal: Journal of Hepatology (2015)
Thymic Recovery and De Novo T Cell Production During the First Year After Unrelated Cord Blood Transplant (UCBT) Predicts Overall Survival: A Multivariate Analysis of 93 Patients Following Myeloablative Conditioning and a Single Unit Graft.
Authors: David A Wilfret, Adam Mendizabal, Kristin M Page, Mel Reese, Richard Vinesett, Joanne Kurtzberg, Paul Szabolcs
Journal: Blood (2009)
Prognostic Impact of Mutant to Wild-Type Ratio and Insertion Site in Acute Myeloid Leukemia with FLT3 Internal Tandem Duplication
Authors: Sabine Kayser, Richard F Schlenk, Jürgen Krauter, Claus-Henning Köhne, Ulrich Germing, Gerhard Held, Heinz A. Horst, Mark Ringhoffer, Marie von Lilienfeld-Toal, Mathias J. Rummel, Katharina Götze, David Nachbaur, Brigitte Schlegelberger, Gudrun Göhring, Helmut R Salih, Hans Martin, Wolfgang Herr, Michael Lübbert, Hans-Jürgen Salwender, Patricia Erdmann, Peter Paschka, Verena I. Gaidzik, Veronica Teleanu, Daniela Späth, Arnold Ganser, Thomas Fischer, Hartmut Döhner, Konstanze Döhner
Journal: Blood (2012)
Exome Sequencing Identifies Recurring DNMT3A Mutations in Adult ETP-ALL
Authors: Martin Neumann, Sandra Heesch, Cornelia Schlee, Stefan Schwartz, Nicola Goekbuget, Dieter Hoelzer, Nikola P Konstandin, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, Helmut Blum, Thorsten Raff, Monika Brueggemann, Wolf-Karsten Hofmann, Stefan K Bohlander, Philipp A Greif, Claudia D Baldus
Journal: Blood (2012)
O121 : The use of a pocket-sized ultrasound device improves physical examination: Results of an in- and outpatient study
Authors: A. Colli, D. Prati, M. Fraquelli, S. Segato, P.P. Vescovi, F. Colombo, C. Balduini, A. Baccarin, S. Della Valle, D. Conte, G. Casazza
Journal: Journal of Hepatology (2015)
Safety and Tolerability of Plerixafor in Combination with Cytarabine and Daunorubicin in Patients with Newly Diagnosed Acute Myeloid Leukemia- Preliminary Results From a Phase I Study
Authors: Geoffrey L. Uy, David Avigan, Jorge E. Cortes, Pamela S. Becker, Robert W. Chen, Jane L. Liesveld, Becker Hewes, Don Johns, Harry Paul Erba
Journal: Blood (2011)
Bendamustine Monotherapy Is Effective As Salvage Therapy in Patients with Refractory / Relapsed Pediatric Hodgkin Lymphoma (HL): A Retrospective Analysis
Authors: Sneha Tandon, Shripad Banavali, Brijesh Arora, Gaurav Narula, Maya Prasad, Tanuja Shet, Sumeet Gujral
Journal: Blood (2015)
A First-In-Man Phase 1 Study Of CUDC-907, a First-In-Class Chemically-Designed Dual Inhibitor Of PI3K and HDAC In Patients With Refractory Or Relapsed Lymphoma and Multiple Myeloma
Authors: Anas Younes, Ian W. Flinn, Yasuhiro Oki, Amanda Copland, Ali Fattaey, Cheng-Jung Lai, Robert Laliberte, Maurizio Voi, Jesus G Berdeja
Journal: Blood (2013)
Use of Genome-Wide Expression Analysis to Optimize An Ex Vivo clinical Protocol for 16,16-Dimethyl Prostaglandin E2 Enhancement of Umbilical Cord Blood In Hematopoietic Stem Cell Transplantation.
Authors: Caroline Desponts, David Robbins, Thuy Le, Annie Chi, Scott Thies, Myriam Armant, Corey Cutler, John Mendlein, Paul Grayson, Pratik S. Multani, Daniel Shoemaker
Journal: Blood (2010)
High-Dose RHAMM-R3 Peptide Peptide Vaccination for Patients with Vaccination for Patients with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Multiple Myeloma (MM) and Chronic Lymphocytic Leukemia (CLL)
Authors: Jochen Greiner, Anita Schmitt, Krzysztof Giannopoulos, Isabel Funk, Marta Heyduk, Markus Rojewski, Jinfei Chen, Marlies Goetz, Martin Bommer, Gerd Ritter, Phillipe Guillaume, Anna Dmoszynska, Hartmut Döhner, Michael Schmitt
Journal: Blood (2008)
Preparation of CaP/pDNA nanoparticles by reverse micro-emulsion method: Optimization of formulation variables using experimental design
Authors: Wenpan Li, Shasha Jing, Xiu Xin, Xirui Zhang, Kang Chen, Dawei Chen, Haiyang Hu
Journal: Asian Journal of Pharmaceutical Sciences (2016)

In this study, the CaP/pDNA nanoparticles were prepared using Triton X-100/Butanol/Cyclohexane/Water reverse microemulsion system. Optimization of preparation conditions was based on evaluation of particle size by Box-Behnken design method. The particle sizes of the optimized CaP/pDNA nanoparticles were found to be 60.23 ± 4.72 nm, polydispersity index was 0.252 and pDNA encapsulate efficiency was more than 90%. The optimized CaP/pDNA nanoparticles have pH sensitivity and biocompatibility. Further, optimized CaP/pDNA nanoparticles showed higher transfection efficiency.
Aspirin use and risk of cholangiocarcinoma: External validation with big data
Authors: Haider Altaii, Sadeer G. Al‐Kindi, Guilherme H. Oliveira, Zaid Yaqoob, Carlos Romero‐Marrero
Journal: Hepatology (2016)

Potential conflict of interest: Nothing to report. To the Editor: We read with interest the paper by Choi and colleagues published in hepatology.1 In an analysis of 2,395 patients with cholangiocarcinoma seen at the Mayo Clinic, the authors report that aspirin use was associated with lower odds of a diagnosis of cholangiocarcinoma. We commend the authors on this important and well‐performed analysis. We attempted to repeat their analysis in a larger, independent, real‐world cohort to provide an external validation of their results. We used a large clinical registry (Explorys, Cleveland, OH) encompassing inpatients and outpatients seen at 26 major health institutions and 360,000 providers in all 50 states.2 The Explorys database draws clinical diagnoses and medication histories from electronic medical records through a proprietary algorithm, which are then mapped into the Systematized Nomenclature of Medicine‐Clinical Terms and RxNORM clinical and drug databases, deidentified, and aggregated. This database has been used and validated in different fields of medicine, including gastroenterology.3 We identified patients with pharmacy data who are at least 50 years old seen at participating institutions from 1999 to 2016. Similarly to Choi et al., we identified diagnoses of cholangiocarcinoma using International Classification of Diseases, Ninth Revision, as follows: 155.1, 156.1, 156.2, 156.8, and 156.9. All patients without cholangiocarcinoma in the database served as controls. We performed a logistic regression model adjusting for the following covariates: age, gender, ethnicity, primary sclerosing cholangitis, inflammatory bowel disease, cirrhosis, smoking, and aspirin use. The Statistical Package for Social Sciences, version 19, was used for the statistical analysis. We identified a total of 8,108,530 patients in the registry, of whom 8,460 (0.001%) had a diagnosis of cholangiocarcinoma and 3,153,600 (39%) used aspirin. After adjusting for covariates, the adjusted odds ratio (aOR) of cholangiocarcinoma was lower in aspirin users compared with nonusers (aOR = 0.86; 95% confidence interval 0.82‐0.90, P < 0.001). Other variables associated with cholangiocarcinoma were age >65 (aOR = 2.48, 2.37‐2.61, P < 0.001), male gender (aOR = 1.19, 1.14‐1.24, P < 0.001), primary sclerosing cholangitis (aOR = 13.8, 13.1‐14.5, P < 0.001), inflammatory bowel disease (aOR = 1.89, 1.70‐2.11, P < 0.001), cirrhosis (aOR = 6.38, 5.95‐6.84, P < 0.001), and smoking (aOR = 1.14, 1.08‐1.21, P < 0.001). Our results support those of Choi et al. using a larger multicenter registry, thus providing external validation for their single‐center analysis. However, similar to their study, our analysis is limited by its retrospective nature and miscoding bias. Prospective studies are required to further elucidate the role of aspirin in the prevention of cholangiocarcinoma.
-52G/A Gene Variant in the β-Defensin-1 (DEBF1) Influences the Development of Severe Acute Graft Versus Host Disease (aGvHD) After Allogeneic Stem Cell Transplantation (Allo-SCT). Functional Association of This Variant with a Low Anti- Inflammatory Response
Authors: Beatriz Martin-Antonio, Damià Romero, David Gallardo, Anna Bosch, Ildefonso Espigado, Ismael Buno, Carolina Martinez-Laperche, Antonio Jimenez-Velasco, Rafael De La Camara, Salut Brunet, Nieto B Jose, Jose Román, Maria Suarez-LLedo, Francesc Fernandez-Avilés, Carmen Martinez, Montserrat Rovira, Alvaro Urbano-Ispizua
Journal: Blood (2011)
Upregulation of eIF4E in Nucleophosmin 1 (NPM1) Haploinsufficient Cells Alters CCAAT Enhancer Binding Protein Alpha (C/EBPα) Activity: Implications for MDS and AML
Authors: Nirmalee Abayasekara, Michelle Levine, Niccolo Bolli, Hong Sun, Matthew Silver, Navid Nia, Paolo Sportoletti, Pier Paolo Pandolfi, Nancy Berliner, Arati Khanna-Gupta
Journal: Blood (2011)
Two Unusual Lymphomas
Authors: C.S. Chim, C. Choy, G.C. Ooi, L.P. Chung, K.K. Wong, R. Liang
Journal: Journal of Clinical Oncology (2000)

Article Tools DIAGNOSIS IN ONCOLOGY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.21.3733 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11054448 Two Unusual Lymphomas Case 2: Pulmonary Intravascular Lymphomatosis C.S. ChimxC.S. ChimSearch for articles by this author , C. ChoyxC. ChoySearch for articles by this author , G.C. OoixG.C. OoiSearch for articles by this author , L.P. ChungxL.P. ChungSearch for articles by this author , K.K. WongxK.K. WongSearch for articles by this author , R. LiangxR. LiangSearch for articles by this author Show More Queen Mary Hospital, The University of Hong Kong, Hong Kong https://doi.org/10.1200/JCO.2000.18.21.3733 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical Oncology
Next Generation Sequence Immunoprofiling of the T-Cell Repertoire in Chronic Lymphocytic Leukemia Supports Selection By Shared Antigenic Elements
Authors: Anna Vardi, Maria Karipidou, Aikaterini Gemenetzi, Elissavet Vlachonikola, Vassileios Bikos, Evangelia Stalika, Eva Koravou, Christos Maramis, Alexandra Siorenta, Achilles Anagnostopoulos, Sarka Pospisilova, Nikolaos Maglaveras, Ioanna Chouvarda, Kostas Stamatopoulos, Anastasia Hadzidimitriou
Journal: Blood (2015)
Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia
Authors: W Wang, Z Chen, Z Hu, C C Yin, S Li, S Bai, C E Bueso-Ramos, L J Medeiros, S Hu
Journal: Blood Cancer Journal (2016)

Chronic myeloid leukemia (CML) is defined by t(9;22)(q34;q11), a genetic abnormality producing BCR-ABL1 fusion on derivative chromosome 22.1 At cytogenetic level, t(9;22)(q34;q11) is the sole abnormality in over 90% of patients in chronic phase (CP). As the disease progresses to accelerated phase (AP) and blast phase (BP), clonal evolution occurs commonly with the emergence of additional cytogenetic abnormalities (ACAs). Approximately 30% of patients with CML-AP and 70–80% of patients with CML-BP have ACAs.2, 3, 4 Among various ACAs, trisomy 8 (+8) and an extra copy of philadelphia chromosome (Ph) are most common.5, 6 Different ACAs have been shown to be associated with different impact on treatment response and survival. Some ACAs are associated with disease progression and treatment resistance, whereas others may simply reflect the genetic instability induced by continuous activation of BCR-ABL1.6, 7, 8 In addition, the interval from initial diagnosis of CML to emergence of ACAs may also be important as the same ACA can have differential impact on tyrosine kinase inhibitor (TKI) treatment and prognosis when it emerges at the time of initial CML diagnosis versus during therapy.6 In the recently updated World Health Organization (WHO) criteria for AP of CML, any new clonal chromosomal abnormality in t(9;22) positive cells that occurs during therapy is considered as a criterion for AP.9